Clinical trial

Lithium for Fracture Treatment: a Double Blind Randomized Controlled Trial

Name
LiFT001
Description
This is a study designed to see if a low dose of Lithium treatment, taken for 2 weeks, can improve fracture healing and improve patients' function and productivity.
Trial arms
Trial start
2017-07-21
Estimated PCD
2024-12-01
Trial end
2025-06-01
Status
Recruiting
Phase
Early phase I
Treatment
Lithium Carbonate
Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
Arms:
Lithium carbonate
Other names:
Lithium
Lactose Placebo
Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
Arms:
Lactose placebo
Other names:
placebo
Size
160
Primary endpoint
radiographic healing of fracture
8 weeks after injury (non-surgical participants) or 8 weeks after surgery (surgical participants)
Eligibility criteria
Inclusion Criteria: 1. Age 18-55 years. 2. ASA (American Society of Anesthesiologists) ≤ 2 class (healthy) prior to injury. 3. Diaphyseal fracture of the humerus, femur or combined tibia/fibula (OTA diaphyseal subclass 2A or B), and clavicle (OTA diaphyseal subclass B1 or B2), with or without nerve injury. 4. Fracture that is primarily closed or open fracture that has complete wound coverage. 5. Randomization ≤14 days from injury or surgery (for surgical patients). 6. Fractures treated surgically or nonsurgically by endochondral/secondary bone healing. 7. For surgical patients, surgery must be within 14 days of injury. Exclusion Criteria: 1. Currently pregnant or breastfeeding. 2. Any past or current malignancy that, in the opinion of an investigator, is not medically controlled. 3. Metabolic bone disease based on clinical history that, in the opinion of an investigator, is not medically controlled. 4. Autoimmune disease that, in the opinion of an investigator, is not medically controlled. 5. Hypothyroidism based on clinical history that, in the opinion of an investigator, is not medically controlled. 6. Renal impairment based on clinical history. 7. Past allergy or adverse reaction to Lithium. 8. Lactose intolerance. 9. Fractures surgically treated with absolute stability/primary bone healing. 10. Isolated tibia or isolated fibula fracture. 11. Currently taking Lithium or anti-psychotic or anti-seizure medication for the treatment of these conditions or at the discretion of an investigator. 12. Inability to comply with study protocol, in the opinion of the investigator(s). 13. Participation in another interventional clinical trial, at the discretion of the principal investigator. 14. Use of concomitant ultrasound or other bone stimulation device.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 160, 'type': 'ESTIMATED'}}
Updated at
2024-01-26

1 organization

2 products

1 indication

Indication
Fracture
Product
Lactose